HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gabriel, M. Articles by Virgolini, I. J. Search for Related Content PubMed PubMed Citation Articles by Gabriel, M. Articles by Virgolini, I. J.

⁶⁸Ga-DOTA-Tyr³-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT

¹ Department of Nuclear Medicine, Innsbruck Medical University, Innsbruck, Austria; and ² Division of Diagnostic Radiology I, Department of Diagnostic Radiology, Innsbruck Medical University, Innsbruck, Austria

Correspondence: For correspondence or reprints contact: Michael Gabriel, MD, Department of Nuclear Medicine, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria. E-mail: michael.gabriel{at}uklibk.ac.at

The aim of this study was to evaluate the diagnostic value of a new somatostatin analog, ⁶⁸Ga-labeled 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-D-Phe¹-Tyr³-octreotide (⁶⁸Ga-DOTA-TOC), for PET in patients with known or suspected neuroendocrine tumors. PET was compared with conventional scintigraphy and dedicated CT. Methods: Eighty-four patients (48 men, 36 women; age range, 28–79 y; mean age ± SD, 58.2 ± 12.2 y) were prospectively studied. For analysis, patients were divided into 3 groups: detection of unknown primary tumor in the presence of clinical or biochemical suspicion of neuroendocrine malignancy (n = 13 patients), initial tumor staging (n = 36 patients), and follow-up after therapy (n = 35 patients). Each patient received 100–150 MBq ⁶⁸Ga-DOTA-TOC. Imaging results of PET were compared with ^99mTc-labeled hydrazinonicotinyl-Tyr³-octreotide (^99mTc-HYNIC-TOC) and ¹¹¹In-DOTA-TOC. CT was also performed on every patient using a multidetector scanner. Each imaging modality was interpreted separately by observers who were unaware of imaging findings before comparison with PET. The gold standard for defining true-positive (TP), true-negative (TN), false-positive (FP), and false-negative (FN) results was based on all available histologic, imaging, and follow-up findings. Results: PET was TP in 69 patients, TN in 12 patients, FP in 1 patient, and FN in 2 patients, indicating a sensitivity of 97%, a specificity of 92%, and an accuracy of 96%. The FP finding was caused by enhanced tracer accumulation in the pancreatic head, and the FN results were obtained in patients with a tumor of the gastrointestinal tract displaying liver metastases. ⁶⁸Ga-DOTA-TOC showed higher diagnostic efficacy compared with SPECT (TP in 37 patients, TN in 12 patients, FP in 1 patient, and FN in 34 patients) and diagnostic CT (TP in 41 patients, TN in 12 patients, FP in 5 patients, and FN in 26 patients). This difference was of statistical significance (P < 0.001). However, the combined use of PET and CT showed the highest overall accuracy. Conclusion: ⁶⁸Ga-DOTA-TOC PET shows a significantly higher detection rate compared with conventional somatostatin receptor scintigraphy and diagnostic CT with clinical impact in a considerable number of patients.

Key Words: ⁶⁸Ga • PET • DOTA-Tyr³-octreotide • neuroendocrine tumors • somatostatin receptor scintigraphy • diagnostic CT

COPYRIGHT © 2007 by the Society of Nuclear Medicine, Inc.

This article has been cited by other articles:

				D. J Kwekkeboom, B. L Kam, M. van Essen, J. J M Teunissen, C. H J van Eijck, R. Valkema, M. de Jong, W. W de Herder, and E. P Krenning Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors Endocr. Relat. Cancer, January 29, 2010; 17(1): R53 - R73. [Abstract] [Full Text] [PDF]

				S. Bhattacharyya, C. Toumpanakis, M. Burke, A. M. Taylor, M. E. Caplin, and J. Davar Features of Carcinoid Heart Disease Identified by 2- and 3-Dimensional Echocardiography and Cardiac MRI Circ Cardiovasc Imaging, January 1, 2010; 3(1): 103 - 111. [Abstract] [Full Text] [PDF]

				I. Kayani, B. G. Conry, A. M. Groves, T. Win, J. Dickson, M. Caplin, and J. B. Bomanji A Comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in Pulmonary Neuroendocrine Tumors J. Nucl. Med., December 1, 2009; 50(12): 1927 - 1932. [Abstract] [Full Text] [PDF]

				M. Gabriel, A. Oberauer, G. Dobrozemsky, C. Decristoforo, D. Putzer, D. Kendler, C. Uprimny, P. Kovacs, R. Bale, and I. J. Virgolini 68Ga-DOTA-Tyr3-Octreotide PET for Assessing Response to Somatostatin-Receptor-Mediated Radionuclide Therapy J. Nucl. Med., September 1, 2009; 50(9): 1427 - 1434. [Abstract] [Full Text] [PDF]

				D. Putzer, M. Gabriel, B. Henninger, D. Kendler, C. Uprimny, G. Dobrozemsky, C. Decristoforo, R. J. Bale, W. Jaschke, and I. J. Virgolini Bone Metastases in Patients with Neuroendocrine Tumor: 68Ga-DOTA-Tyr3-Octreotide PET in Comparison to CT and Bone Scintigraphy J. Nucl. Med., August 1, 2009; 50(8): 1214 - 1221. [Abstract] [Full Text] [PDF]

				S. Kauhanen, M. Seppanen, J. Ovaska, H. Minn, J. Bergman, P. Korsoff, P. Salmela, J. Saltevo, T. Sane, M. Valimaki, et al. The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors Endocr. Relat. Cancer, March 1, 2009; 16(1): 255 - 265. [Abstract] [Full Text] [PDF]

				L. Chen, F. Li, H. Zhuang, H. Jing, Y. Du, and Z. Zeng 99mTc-HYNIC-TOC Scintigraphy Is Superior to 131I-MIBG Imaging in the Evaluation of Extraadrenal Pheochromocytoma J. Nucl. Med., March 1, 2009; 50(3): 397 - 400. [Abstract] [Full Text] [PDF]

				J. V. Frangioni New Technologies for Human Cancer Imaging J. Clin. Oncol., August 20, 2008; 26(24): 4012 - 4021. [Abstract] [Full Text] [PDF]

				S. Leboulleux, C. Dromain, A. L. Vataire, D. Malka, A. Auperin, J. Lumbroso, P. Duvillard, D. Elias, D. M. Hartl, T. De Baere, et al. Prediction and Diagnosis of Bone Metastases in Well-Differentiated Gastro-Entero-Pancreatic Endocrine Cancer: A Prospective Comparison of Whole Body Magnetic Resonance Imaging and Somatostatin Receptor Scintigraphy J. Clin. Endocrinol. Metab., August 1, 2008; 93(8): 3021 - 3028. [Abstract] [Full Text] [PDF]

				D. A. Mankoff, J. M. Link, H. M. Linden, L. Sundararajan, and K. A. Krohn Tumor Receptor Imaging J. Nucl. Med., June 1, 2008; 49(Suppl_2): 149S - 163S. [Abstract] [Full Text] [PDF]

				G. Khanna, D. Bushnell, and M. S. O'Dorisio Utility of Radiolabeled Somatostatin Receptor Analogues for Staging/Restaging and Treatment of Somatostatin Receptor-Positive Pediatric Tumors Oncologist, April 1, 2008; 13(4): 382 - 389. [Abstract] [Full Text] [PDF]

				O. Schillaci Somatostatin Receptor Imaging in Patients with Neuroendocrine Tumors: Not Only SPECT? J. Nucl. Med., April 1, 2007; 48(4): 498 - 500. [Full Text] [PDF]